secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kronos Bio, Inc. (—)
CIK:        0001741830
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001741830-24-000070
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kronos Bio cuts 83% of workforce; CEO Bischofberger resigns, Knobelman named interim CEO
--------------------------------------------------------------------------------

- Board approved ~83% workforce reduction expected to be substantially completed by Dec 31, 2024.
- Company expects $3.7M charge for severance and benefits; payments substantially complete by Q1 2025.
- CEO Norbert Bischofberger resigns effective Dec 3, 2024; receives $899K special transaction bonus.
- CFO/COO Deborah Knobelman appointed President and Interim CEO; salary raised to $525K, bonus target 50%.
- Knobelman also eligible for $300K special transaction bonus upon change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1741830/000174183024000070/0001741830-24-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1741830/000174183024000070/kron-20241122.htm
  HTML page:      https://secwatch.observer/filing/0001741830-24-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer